Supported by OpenAI CEO Sam Altman, biotech startup Retro Biosciences is in the midst of a $1 billion Series A funding round, furthering its ambition to extend human lifespan. Previously, Altman invested $180 million in seed funding for the company. Retro Biosciences aims not only to extend human lifespan but also to prolong healthy lifespan, ensuring people remain in good health towards the end of their lives.

In the biotech field, leveraging artificial intelligence to accelerate research has become a new norm. Recently, biotech company Cradle announced it has completed a $73 million funding round, aiming to further expand its laboratories and team. Founded in 2022, Cradle is dedicated to exploring the applications of language models in biotechnology. Founder and CEO Stef van Grieken has vividly referred to the combinations of amino acids and bases as an 'alien programming language', although this language can also be processed by AI models.

Now, scientists can precisely "design" proteins as if they are programming. This is no longer science fiction but a reality being created by the Dutch company Cradle. In the grand tapestry of biotechnology, Cradle's founder, Stefan van Groningen, likens proteins to an "alien programming language." His team is utilizing artificial intelligence to decipher this mysterious language, bringing revolutionary changes to biotechnology. Traditional protein development has been like a long and costly blind exploration. Researchers must go through dozens of experimental rounds, each of which may...

Biotechnology company Chai Discovery has received nearly $30 million in investment from Thrive Capital and OpenAI within six months of its founding. The company focuses on the application of biotechnology in drug development, developing innovative technologies that can predict biochemical molecular structures and reprogram molecular interactions, aiming to transform biology into 'engineering.' Chai Discovery's goal is to accelerate and optimize the drug development process by enhancing drug molecule design through technologies such as artificial intelligence and machine learning.